EGFR amplification is common in glioblastoma and represents a therapeutic challenge, conferring resistance to targeted treatment. A new study reveals that the same locus hides the HELDR lncRNA, which epigenetically activates KAT7 to drive growth independently of EGFR. Targeting HELDR or KAT7 may improve anti-EGFR therapies in glioblastoma.
- Andrew Dhawan
- Justin D. Lathia